Hemodynamic Effects of Intra-aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
- 1 April 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Shock
- Vol. 37 (4) , 378-384
- https://doi.org/10.1097/shk.0b013e31824a67af
Abstract
We conducted the IABP Cardiogenic Shock Trial (ClinicalTrials.gov ID NCT00469248) as a prospective, randomized, monocentric clinical trial to determine the hemodynamic effects of additional intra-aortic balloon pump (IABP) treatment and its effects on severity of disease in patients with acute myocardial infarction complicated by cardiogenic shock (CS). Intra-aortic balloon pump counterpulsation is recommended in patients with CS complicating myocardial infarction. However, there are only limited randomized controlled trial data available supporting the efficacy of IABP following percutaneous coronary intervention (PCI) and its impact on hemodynamic parameters in patients with CS. Percutaneous coronary intervention of infarct-related artery was performed in 40 patients with acute myocardial infarction complicated by CS, within 12 h of onset of hemodynamic instability. Serial hemodynamic parameters were determined over the next 4 days and compared in patients receiving medical treatment alone with those treated with additional intra-aortic balloon counterpulsation. There were no significant differences among severity of disease (i.e., Acute Physiology and Chronic Health Evaluation II score) initially and no differences among both groups for disease improvement. We observed significant temporal improvements of cardiac output (4.8 ± 0.5 to 6.0 ± 0.5 L/min), systemic vascular resistance (926 ± 73 to 769 ± 101 dyn · s(-1) · cm(-5)), and the prognosis-validated cardiac power output (0.78 ± 0.06 to 1.01 ± 0.2 W) within the IABP group. However, there were no significant differences between the IABP group and the medical-alone group. Additional IABP treatment did not result in a significant hemodynamic improvement compared with medical therapy alone in a randomized prospective trial in patients with CS following PCI. Therefore, the use and recommendation for IABP treatment in CS remain unclear.Keywords
This publication has 32 references indexed in Scilit:
- Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome*Critical Care Medicine, 2010
- Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock*Critical Care Medicine, 2007
- Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac diseaseAmerican Heart Journal, 2007
- Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial InfarctionJAMA, 2006
- Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registryEuropean Heart Journal, 2006
- ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive SummaryJournal of the American College of Cardiology, 2004
- Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic ShockNew England Journal of Medicine, 1999
- Intraaortic balloon pumping for cardiac support: Trends in practice and outcome, 1968 to 1995The Journal of Thoracic and Cardiovascular Surgery, 1997
- Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: Relationship to infarct extent and mortalityAmerican Heart Journal, 1981
- Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure.Circulation, 1977